Search

Your search keyword '"Skoda, Ondrej"' showing total 40 results

Search Constraints

Start Over You searched for: Author "Skoda, Ondrej" Remove constraint Author: "Skoda, Ondrej"
40 results on '"Skoda, Ondrej"'

Search Results

1. Effect of Asymptomatic and Symptomatic COVID-19 on Acute Ischemic Stroke Revascularization Outcomes

3. Safety and efficacy of GABAA α5 antagonist S44819 in patients with ischaemic stroke: a multicentre, double-blind, randomised, placebo-controlled trial

4. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting

5. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

6. Delivery of acute ischaemic stroke treatments in the European region in 2019 and 2020

7. Global Impact of the COVID-19 Pandemic on Stroke Volumes and Cerebrovascular Events: A 1-Year Follow-up

8. Global impact of the COVID-19 pandemic on stroke volumes and cerebrovascular events

11. Risk for Major Bleeding in Patients Receiving Ticagrelor Compared With Aspirin After Transient Ischemic Attack or Acute Ischemic Stroke in the SOCRATES Study (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes)

12. The decline in stroke hospitalization due to COVID‐19 is unrelated to COVID‐19 intensity.

13. Safety and Outcome of Revascularization Treatment in Patients With Acute Ischemic Stroke and COVID-19: The Global COVID-19 Stroke Registry

16. Global Impact of COVID-19 on Stroke Care and IV Thrombolysis

17. Treat COVID-19, but Not Only COVID-19: Stroke Matters as Well

18. sj-pdf-2-eso-10.1177_23969873211007684 - Supplemental material for Stroke 20 20: Implementation goals for intravenous thrombolysis

19. Global Impact of COVID-19 on Stroke Care and Intravenous Thrombolysis

20. sj-pdf-1-eso-10.1177_23969873211007684 - Supplemental material for Stroke 20 20: Implementation goals for intravenous thrombolysis

21. Global impact of the COVID-19 pandemic on stroke care and intravenous thrombolysis

23. Safety and Outcome of Revascularization Treatment in Patients With Acute Ischemic Stroke and COVID-19

24. Global impact of the COVID-19 pandemic on stroke care and intravenous thrombolysis (1462)

25. Stroke 20 20: Implementation goals for intravenous thrombolysis

27. Safety and efficacy of GABAA α5 antagonist S44819 in patients with ischaemic stroke: a multicentre, double-blind, randomised, placebo-controlled trial

28. Treat COVID-19, but Not Only COVID-19: Stroke Matters as Well.

29. Table 2 -Supplemental material for European Stroke Organisation certification of stroke units and stroke centres

30. Table 1 -Supplemental material for European Stroke Organisation certification of stroke units and stroke centres

31. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

32. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting

34. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

35. Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack

36. Global impact of the COVID-19 pandemic on stroke care and intravenous thrombolysis

38. Ofatumumab versus Teriflunomide in Multiple Sclerosis

39. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Catalog

Books, media, physical & digital resources